Kalaris Therapeutics, Inc.

EcoR1 Capital's full exit from Kalaris Therapeutics removes a high-profile growth-stage crossover investor from the cap table, a meaningful negative signal for a name still requiring clinical de-risking. Despite the exit, four specialist funds remain holders — Redmile, Tang, RTW, and now without EcoR1 — suggesting residual conviction in the pipeline, though the departure of a crossover fund often signals concerns about near-term catalyst timing or financing trajectory.

Unlock full AI analysis — 14-day free trial